Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open

Published:2019-10-29 Issue:2 Volume:51 Page:271-280
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Sands Bruce E.¹,Armuzzi Alessandro²,Marshall John K.³,Lindsay James O.⁴,Sandborn William J.⁵^ORCID,Danese Silvio⁶^ORCID,Panés Julián⁷^ORCID,Bressler Brian⁸,Colombel Jean-Frédéric¹^ORCID,Lawendy Nervin⁹,Maller Eric⁹,Zhang Haiying⁹,Chan Gary⁹,Salese Leonardo⁹,Tsilkos Konstantinos⁹,Marren Amy⁹,Su Chinyu⁹

Affiliation:

1. Icahn School of Medicine at Mount Sinai; New York NY USA

2. Fondazione Policlinico Universitario A. Gemelli IRCCS; Università Cattolica del Sacro Cuore; Rome Italy

3. Farncombe Family Digestive Health Research Institute; McMaster University; Hamilton ON Canada

4. The Royal London Hospital; Barts Health NHS Trust; London UK

5. University of California, San Diego; La Jolla CA USA

6. Humanitas Research Hospital; Rozzano Italy

7. Hospital Clínic de Barcelona; Barcelona Spain

8. University of British Columbia; Vancouver BC Canada

9. Pfizer Inc; Collegeville PA USA

Funder

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15555/fullpdf

Reference20 articles.

1. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 2: current management;Harbord;J Crohns Colitis,2017

2. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee;Kornbluth;Am J Gastroenterol,2010

3. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases;Pariente;Aliment Pharmacol Ther,2014

4. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease;Torres;Gastroenterology,2015

5. Tofacitinib as induction and maintenance therapy for ulcerative colitis;Sandborn;N Engl J Med,2017

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined Advanced Targeted Therapy in Inflammatory Bowel Diseases: An Extensive Update;Inflammatory Bowel Diseases;2024-08-29

2. Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study;Intestinal Research;2024-07-31

3. Approach to loss of response to advanced therapies in inflammatory bowel disease;World Journal of Gastroenterology;2024-06-14

4. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis;World Journal of Gastroenterology;2024-04-07

5. Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future;Future Pharmacology;2024-03-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3